FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979571657> ?p ?o ?g. }

• W2979571657 abstract "Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, accounting for approximately 30% of newly diagnosed cases in the United States. DLBCL can progress quickly and advanced cases are inconsistently cured with current therapies. Ibrutinib, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is approved in the US and EU for patients with previously-treated mantle cell lymphoma and chronic lymphocytic leukemia (CLL) who have had one prior treatment, CLL with 17p deletion, and Waldenström macroglobulinemia. The activated B-cell (ABC) subtype of DLBCL is considered especially high risk and is characterized by chronic active B-cell receptor signaling, which is blocked by ibrutinib. Recent phase 2 trial results of ibrutinib as a single agent in DLBCL patients show an overall response rate of 41% in the ABC subtype (Wilson et al. ASH 2012; Wilson et al. Nat Med, 2015). Through targeted deep sequencing, we investigated the impact of baseline mutations of 317 targeted genes on clinical response of 51 DLBCL patients treated with ibrutinib. Based on our mutation impact analysis, we identified potential biomarkers for predicting DLBCL patient response to ibrutinib. In particular, we found sets of gene mutation patterns indicating poor (or good) clinical response across all subtypes (ABC, germinal-center B-cell-like [GCB], non-GCB) of DLBCL as well as uniquely within a subtype. Methods: H&E-stained slides from DLBCL patients enrolled in either PCYC-04753 (NCT00849654) or PCYC-1106 (NCT01325701) were reviewed to ensure sufficient nucleated cellularity and tumor content. DNA and RNA were extracted from unstained sections of FFPE DLBCL tumor biopsies. Sequencing was performed using the FoundationOne™ Heme panel following the validated NGS-based protocol to interrogate complete DNA coding sequences of 405 genes, as well as selected introns of 31 genes involved in rearrangements. RNA sequences of 265 commonly rearranged genes were analyzed to identify gene fusions. A subgroup of samples were analyzed on earlier versions of the FoundationOne™ panels where only DNA was extracted and sequenced. Sequence data was processed and analyzed for base substitutions, insertions, deletions, copy-number alterations, and selected gene fusions. Mutation impact indices (MII) of 317 genes were calculated and plotted for overall gene mutation pattern recognition. Chi-square association tests were performed on cases where sufficient sample sizes were available to determine statistical significance of mutation impact. DLBCL subtype classifications by gene expression profiling (GEP) and Hans' IHC were investigated and compared. For GEP, we used OmicSoft ArrayStudio's classification module to build linear discriminant analysis (LDA) model/classifier and neural networks with 5-fold cross validation procedure for model selection. The LDA was the best performing model and was selected for final GEP classification. Since only 29 (of 51) patients had central lab Hans' IHC classification information, we compared trends of the mutation impact results based on Hans' classification and GEP classification. Results: Single or multiple gene MII were generated from baseline tumor biopsies from DLBCL patients treated with single agent ibrutinib. The MII were generally consistent between GEP or Hans' IHC classification of tumor biopsies. We found novel baseline gene mutations associated with poor clinical response (SD or PD) to ibrutinib. These genes were involved in regulation of transcription (eg, mutations in EP300 in all DLBCL subtypes combined group [p=0.034], mutations in RB1 in ABC-DLBCL [p=0.031]), epigenetic modification (eg, mutations in MLL2 in ABC-DLBCL [p=0.053]), programmed cell death (mutations in BCL2 in all DLBCL subtypes [p=0.096]), and PI3K-AKT-mTOR pathway (eg, mutations in TSC2 in ABC-DLBCL [p=0.031]). Mutations identified as indicating good clinical response include mutations in CD79B (p=0.072) and MYD88 (p=0.024) in ABC-DLBCL. Co-existence of MYD88 and CD79B mutations (double-mutants) in ABC-DLBCL showed a stronger association to good clinical response (p=0.004) consistent with recent observations from Wilson et al. ASH 2012 & Nat Med, 2015. Conclusions: Our investigation reveals unique mutation patterns that underlie DLBCL subtypes and highlights the need for personalized medicine approaches to treating DLBCL patients. Disclosures Cheung: Pharmacyclics LLC, an AbbVie Company: Employment. Schweighofer:Pharmacyclics LLC, an AbbVie Company: Employment. Wu:Pharmacyclics LLC, an AbbVie Company: Employment. Kuo:Pharmacyclics LLC, an AbbVie Company: Employment. Eckert:Pharmacyclics LLC, an AbbVie Company: Employment. Balasubramanian:Pharmacyclics LLC, an AbbVie Company: Equity Ownership; Janssen: Employment, Equity Ownership. Ricci:Janssen: Employment, Equity Ownership, Patents & Royalties. Liang:Pharmacyclics LLC, an AbbVie Company: Employment. Beaupre:Pharmacyclics LLC, an AbbVie Company: Employment. Chang:Pharmacyclics LLC, an AbbVie Company: Employment." @default.
• W2979571657 created "2019-10-18" @default.
• W2979571657 creator A5002011167 @default.
• W2979571657 creator A5002211781 @default.
• W2979571657 creator A5027725333 @default.
• W2979571657 creator A5028012876 @default.
• W2979571657 creator A5047826411 @default.
• W2979571657 creator A5060891436 @default.
• W2979571657 creator A5062625211 @default.
• W2979571657 creator A5076291201 @default.
• W2979571657 creator A5079048180 @default.
• W2979571657 creator A5080782271 @default.
• W2979571657 date "2015-12-03" @default.
• W2979571657 modified "2023-09-26" @default.
• W2979571657 title "Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib" @default.
• W2979571657 doi "https://doi.org/10.1182/blood.v126.23.2642.2642" @default.
• W2979571657 hasPublicationYear "2015" @default.
• W2979571657 type Work @default.
• W2979571657 sameAs 2979571657 @default.
• W2979571657 citedByCount "0" @default.
• W2979571657 crossrefType "journal-article" @default.
• W2979571657 hasAuthorship W2979571657A5002011167 @default.
• W2979571657 hasAuthorship W2979571657A5002211781 @default.
• W2979571657 hasAuthorship W2979571657A5027725333 @default.
• W2979571657 hasAuthorship W2979571657A5028012876 @default.
• W2979571657 hasAuthorship W2979571657A5047826411 @default.
• W2979571657 hasAuthorship W2979571657A5060891436 @default.
• W2979571657 hasAuthorship W2979571657A5062625211 @default.
• W2979571657 hasAuthorship W2979571657A5076291201 @default.
• W2979571657 hasAuthorship W2979571657A5079048180 @default.
• W2979571657 hasAuthorship W2979571657A5080782271 @default.
• W2979571657 hasConcept C126322002 @default.
• W2979571657 hasConcept C143998085 @default.
• W2979571657 hasConcept C170493617 @default.
• W2979571657 hasConcept C2777525834 @default.
• W2979571657 hasConcept C2777938653 @default.
• W2979571657 hasConcept C2778461978 @default.
• W2979571657 hasConcept C2778559949 @default.
• W2979571657 hasConcept C2779338263 @default.
• W2979571657 hasConcept C2779878957 @default.
• W2979571657 hasConcept C42362537 @default.
• W2979571657 hasConcept C502942594 @default.
• W2979571657 hasConcept C71924100 @default.
• W2979571657 hasConcept C90059517 @default.
• W2979571657 hasConceptScore W2979571657C126322002 @default.
• W2979571657 hasConceptScore W2979571657C143998085 @default.
• W2979571657 hasConceptScore W2979571657C170493617 @default.
• W2979571657 hasConceptScore W2979571657C2777525834 @default.
• W2979571657 hasConceptScore W2979571657C2777938653 @default.
• W2979571657 hasConceptScore W2979571657C2778461978 @default.
• W2979571657 hasConceptScore W2979571657C2778559949 @default.
• W2979571657 hasConceptScore W2979571657C2779338263 @default.
• W2979571657 hasConceptScore W2979571657C2779878957 @default.
• W2979571657 hasConceptScore W2979571657C42362537 @default.
• W2979571657 hasConceptScore W2979571657C502942594 @default.
• W2979571657 hasConceptScore W2979571657C71924100 @default.
• W2979571657 hasConceptScore W2979571657C90059517 @default.
• W2979571657 hasLocation W29795716571 @default.
• W2979571657 hasOpenAccess W2979571657 @default.
• W2979571657 hasPrimaryLocation W29795716571 @default.
• W2979571657 hasRelatedWork W146907351 @default.
• W2979571657 hasRelatedWork W2518084726 @default.
• W2979571657 hasRelatedWork W2546061993 @default.
• W2979571657 hasRelatedWork W2580052588 @default.
• W2979571657 hasRelatedWork W2596619313 @default.
• W2979571657 hasRelatedWork W2602310116 @default.
• W2979571657 hasRelatedWork W2612317631 @default.
• W2979571657 hasRelatedWork W2615278420 @default.
• W2979571657 hasRelatedWork W2626615329 @default.
• W2979571657 hasRelatedWork W2738881656 @default.
• W2979571657 hasRelatedWork W2905414294 @default.
• W2979571657 hasRelatedWork W2945478885 @default.
• W2979571657 hasRelatedWork W2954635504 @default.
• W2979571657 hasRelatedWork W2979484159 @default.
• W2979571657 hasRelatedWork W2979948337 @default.
• W2979571657 hasRelatedWork W2980183735 @default.
• W2979571657 hasRelatedWork W2980223642 @default.
• W2979571657 hasRelatedWork W2985279452 @default.
• W2979571657 hasRelatedWork W3081061792 @default.
• W2979571657 hasRelatedWork W3106654929 @default.
• W2979571657 isParatext "false" @default.
• W2979571657 isRetracted "false" @default.
• W2979571657 magId "2979571657" @default.
• W2979571657 workType "article" @default.